Building the wellness and clinical gold standards to measure muscle wasting and the impact of its treatment. A Comprehensive, Painless, Portable Measure of Muscle Quality. Even @Home.

Our Myolex® mission is to build the clinical standard to comprehensively assess and display changes in skeletal muscle composition and micro infrastructure to aid in the diagnosis, prognosis, and monitoring of neuromuscular disorders and muscle wasting diseases.

The Myolex EIM impedance-based approach is very sensitive to deteriorating effects of injury and disease. EIM has demonstrated that it can provide predictive variables to assess myofiber size and distribution with good accuracy, particularly in diseases where myofiber atrophy is the predominant histological feature.

Aug 27, 2024 · Myolex has developed the first quantitative, sensitive, painless, portable for in-home use, muscle quality assessment device that is specifically designed to non-invasively and comprehensively detect and track single muscle wasting that can result from aging, disease, obesity drug weight loss, and sport or work-related injury.

Myolex®’s mScan is an accurate, non-invasive, efficient, and por¬ta¬ble device, and comes with iPad, unique App, and custom, disposable foam electrodes that help users col¬lect data from multiple muscles within minutes.

Myolex Inc. develops devices used to assess muscle condition. Leveraging our large database of nearly 10 million muscle scans, Myolex’s patented technology, Electrical Impedance Myography (EIM), supports a vast and growing potential of applications ranging from elite athletics, sports medicine & physical therapy, medical orthopedics, and

Myolex® EIM is a patented device technology and SaaS data analytics platform that is built to disrupt skeletal muscle measurement by becoming the clinical and wellness standard to aid in the...

Treatment of increased tone of skeletal muscles due to organic neurological disorders (injury of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis). Treatment of muscular spasm, muscular contracture, rigidity, spinal automatism.

BOSTON, July 26, 2023 /PRNewswire/ -- Myolex ® Inc. announced today that Dave Dickinson has been named the company’s Chief Executive Officer and Board Director. An award-winning innovator and seasoned Fortune 100 healthcare executive, Dave brings extensive startup CEO, product development, marketing, and strategic partnership experience to ...

Through numerous IRB-approved clinical trials, Myolex EIM has been used to help discriminate between healthy and diseased muscle, and to assess tissue degradation and progressive muscle weakness over time.